TABLE 1

Efficacy of 15 drugs and antiviral compounds against four EV-D68 strains

Drug or antiviral compoundMean EC50 ± SD (μM)
USA-MO/18947USA-MO/18949USA-IL/18956Fermon
EV or RV capsid inhibitors
    Pleconarila,b4.44 ± 0.556.09 ± 0.266.11 ± 1.050.38 ± 0.01
    Pocapavira>10>10>10>10
    Vapendavira>10>10>10>10
EV or RV protease inhibitors
    Rupintrivira0.0046 ± 0.00160.0015 ± 0.0030.0037 ± 0.0070.002 ± 0.0005
    V-7404c0.026 ± 0.0040.027 ± 0.0080.024 ± 0.0070.0035 ± 0.0006
Influenza virus inhibitors
    Amantidined>10>10>10>10
    Arbidola,e>10>10>10>10
    DAS181a0.0036 ± 0.00150.0026 ± 0.00120.004 ± 0.00160.0012 ± 0.0009
    Favipiravira>10>10>10>10
    Oseltamivird>10>10>10>10
Approved for other indications
    Fluoxetined0.53 ± 0.150.64 ± 0.171.05 ± 0.20.34 ± 0.04
    Formoterol fumarated>10>10>10>10
    Itraconazoled>10>10>10>10
    Mefloquined>10>10>10>10
    Nitazoxanided>10>10>10>10
  • a Completed a phase II clinical trial but not yet FDA approved.

  • b In HeLa H1 cells, the EC50s of pleconaril for the four strains were 0.131 ± 0.024, 0.358 ± 0.036, 0.321 ± 0.094, 0.36 ± 0.021 μM, respectively. For other compounds, the values were not significantly different in the two cell lines (data not shown).

  • c Completed a phase I clinical safety trial.

  • d FDA approved for an indication other than EV or RV infection.

  • e Licensed for human use in Russia and China.